Key facts
- This page summarizes Adam Sragovicz's Form 4 filing for CONDUIT PHARMACEUTICALS INC. (CDT).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 15 May 2024, 16:30.
Adam Sragovicz - 15 May 2024 Form 4 Insider Report for CONDUIT PHARMACEUTICALS INC. (CDT)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- CDT
- Reported as of
- 15 May 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 15 May 2024, 16:30:49 UTC
- Prior SEC filing
- 05 Dec 2023
- Next SEC filing
- 09 Aug 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Adam Sragovicz
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Adam Sragovicz filed Form 4 for CONDUIT PHARMACEUTICALS INC. (CDT) on 15 May 2024.
Change
- Previous filing in this sequence was filed on 05 Dec 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CDT
transaction
Restricted Stock Units
Disposed to Issuer
- Transaction value
- $0
- Shares
- -74,545
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 15 May 2024
- Ownership
- Direct
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Adam Sragovicz is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.